The Sunnyvale, CA-based radiation oncology company posted a net loss of 9 cents per share, wider than the loss of 7 cents per share that analysts had forecast.
Revenue for the period was $95 million, below Wall Street's estimates of $99 million.
For fiscal 2017, the company sees revenue between $410 million and $420 million. Analysts are expecting revenue of $432 million.
Shares of Accuray closed up on heavy trading volume Wednesday. About 1.03 million of the company's shares changed hands today vs. its average volume of 509,545 shares per day.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D+ on the stock.
The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: ARAY